Medical Access and Reimbursement in Japan

Currently classified as a strictly controlled substance under Japan's narcotics/psychotropics control framework with no authorised medical use outside of approved clinical research. The Narcotics and Psychotropics Control Law is the primary domestic statute that governs most non‑cannabis psychedelics and proscribes manufacture, import, distribution and possession outside tightly regulated channels #. Psilocybin (mushrooms) was specifically brought under prohibition in the early 2000s following case reports and regulatory action; there is no national medical reimbursement pathway for psilocybin therapy in Japan and clinical access is limited to formally approved clinical trials. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is regulated under Japan's narcotics/psychotropics control framework and is not available through routine medical practice or public reimbursement; any investigational MDMA‑assisted therapy would require explicit regulatory approval and trial authorization. #

Esketamine (the S‑enantiomer marketed internationally as SPRAVATO) has been studied in Japanese populations (phase 2b/phase 3 programmes have included Japanese sites) and the international regulatory history shows approvals in some jurisdictions (e.g., FDA) for treatment‑resistant depression, but there is no clear, consistently published PMDA/MHLW marketing authorisation record available in publicly indexed PMDA lists that confirms a routine Japanese marketing authorisation with national reimbursement at the time of this report. Clinical trial data including a randomized Phase 2b study in Japanese patients are published and describe esketamine as an investigational add‑on for treatment‑resistant depression in Japan #. Patent and regulatory commentary has noted that, as of mid‑2021, esketamine had not obtained approval in Japan and Japanese trial data have been a focus of regulatory review #. Because national reimbursement requires an MHLW/PMDA authorisation and subsequent price/benefit review, and no official PMDA product listing/MPA notice confirming a reimbursed marketing authorisation could be located in public PMDA search listings during the web search for this report, routine reimbursed access in the Japanese national health insurance system should be considered not established and access limited to clinical trials or case‑by‑case investigational/compassionate pathways until an explicit PMDA/MHLW approval and reimbursement listing is published. (If you need a definitive PMDA approval confirmation for a specific trade name or dossier, I can perform a targeted PMDA/PMDA medical product search and return the product listing URL.)

Ketamine is an approved and widely used anaesthetic and analgesic in Japan (marketed formulations and product monographs exist for ketamine hydrochloride for clinical use). KEGG drug and Japanese product listings document ketamine formulations and brand names used in Japanese clinical practice as an anaesthetic agent. #.

Clinical/psychiatric use: racemic ketamine is used off‑label in psychiatric settings internationally and in Japan there are published clinical studies and institutional protocols exploring sub‑anesthetic ketamine for depression; however, ketamine is not reimbursed nationally as an antidepressant indication and its psychiatric use is generally either off‑label clinical practice paid by private patients or conducted under approved clinical research protocols. Medical administration requires licensed medical practitioners and, where applicable, compliance with narcotics/medical supply regulations; non‑medical possession or distribution remains prohibited under Japan's control statutes. (Sources documenting clinical research and the approved medical products are cited above.) # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and DMT‑containing preparations such as traditional ayahuasca brews) are controlled under Japan's narcotics/psychotropics framework and there is no legal medical/clinical reimbursement pathway for DMT therapy in Japan. Any lawful human use would require formal clinical trial approval and regulatory permitting. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated under the same stringent control mindset as other synthetic tryptamines in Japan; there is no authorised clinical use or reimbursement pathway. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not available through the Japanese medical system and any therapeutic use would require approved clinical research authorization; possession/supply outside these channels would be unlawful. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca contains DMT (a controlled tryptamine), importation, possession and use outside an approved clinical or research setting would be prohibited in Japan. There is no recognised religious exemption or medical reimbursement pathway for ayahuasca in Japan. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and mescaline‑containing cacti) are controlled substances in Japan and are not part of any national medical reimbursement programme; authorised human use would require clinical trial approval. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Various 2C‑series phenethylamines (e.g., 2C‑B) have been scheduled in Japan historically and are treated as illicit psychotropic substances; there is no medical/reimbursement access for 2C‑series compounds. # #